Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Intas Pharma

- PMLiVE

Astellas buys Ganymed to boost immuno-oncology pipeline

Enters into €1.28bn deal for access to first-in-class gastric cancer blockbuster candidate

- PMLiVE

UK to cut wait to innovative treatments by four years

Proposals in the Accelerated Access Review aim to speed up access to innovation

Novartis Gehry Building

Novartis says its biosimilar sales should reach $1bn this year

Four-drug portfolio grew by 40% to $262m in the quarter

- PMLiVE

Halesway changes name to FCB Halesway

Move aligns agency more closely with its parent company FCB Health

- PMLiVE

FDA halts study of Teva and Regeneron’s pain drug fasinumab

Firms to redesign phase III trial excluding patients with advanced osteoarthritis after set back

Bristol-Myers Squibb (BMS) building

NICE turns down Opdivo but offers CDF hope

Wants more cost-effectiveness data to be gathered

- PMLiVE

NICE rejects Imbruvica for non-Hodgkin’s lymphoma

Draft guidance cites insufficient cost-effectiveness evidence for J&J’s drug

National Institute for Health and Care Excellence NICE logo

NICE to create fast track for most cost-effective new drugs

Proposes accelerated appraisal process for drugs with QALY of £10,000 or less

- PMLiVE

Health activators lack confidence in primary healthcare

Survey finds patient decision-makers increasingly turning to non-traditional sources

- PMLiVE

Teva appoints UK & Ireland general manager

Promotes UK chief operating officer Kim Innes

- PMLiVE

Pfizer to sell off Hospira’s infusions business – and its New York HQ

Infusion therapy specialist ICU Medical buys up unit in $1bn deal

- PMLiVE

Regional NHS pulmonary rehabilitation video campaign launched

Aims to boost referral rates among GPs in the north east of England

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links